Furthermore, combining information from mpMRI and the PSMA-PET might offer complementary information in the diagnosis of intermediate and high-risk PCa patients, as well as detect tumor recurrence, overcoming the limitation of a single technique to the analysis of the tumor and TME within the whole prostate gland [87,91,93,96,97]. This evidence concerns the gene FOLH1 and neoplasm.